Company intelligence / Profile preview

Cartago Biotech

Cartago, Cartago, Costa Rica

Ownership: Private
Development stage: Other

Overview

Cartago Biotech is a preclinical-stage biotechnology company focused on developing disease-modifying therapies for osteoarthritis and other degenerative joint diseases. The company utilizes a proprietary platform designed to deliver therapeutic proteins directly to the cartilage, aiming to halt progression and promote tissue repair. By targeting the extracellular matrix of the joint, Cartago's technology seeks to overcome the limitations of current treatments that only address symptoms. The company is headquartered in Costa Rica and is advancing its lead programs toward clinical validation.

Therapeutic areas: Rheumatology
Modalities: Recombinant proteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on Cartago Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cartago Biotech.

Explore the full profile